Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making

Author： Annemans Lieven  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.5, 2008-01, pp. : 409-423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aromatase Inhibitors in Breast Cancer: A Review of Cost Considerations and Cost Effectiveness

By Karnon Jonathan  

PharmacoEconomics, Vol. 24, Iss. 3, 2006-01 ,pp. : 215-232

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair   Millward Michael J.  

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

By Norum Jan  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1617-1625

Informa Healthcare

Access to resources Recommend Favorite

Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women

By  

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 6, 2008-06 ,pp. : 564-574

Bentham Science Publishers

Access to resources Recommend Favorite

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

By Ligibel Jennifer A.   Winer Eric P.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 2, 2003-04 ,pp. : 215-221

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite